Table 1.
Summary of clinical trials involving CTA that are completed or active
| NCT NUMBER | INTERVENTION | PHASE | LAST UPDATE POSTED | SPONSORS |
|---|---|---|---|---|
| NCT03159585 | NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy | I | 2020 | Zhujiang Hospital |
| Xiangxue Pharmaceutical (and more) | ||||
| NCT01536054 | ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine | I | 2020 | Roswell Park Cancer Institute |
| NCT02650986 | Autologous NY-ESO-1 TCR/dnTGFbetaRII transgenic T cells | I/II | 2020 | Roswell Park Cancer Institute |
| NCT03691376 | Autologous NY-ESO-1-specific CD8-positive T Lymphocytes | I | 2020 | Roswell Park Cancer Institute, Buffalo, New York, United States |
| NCT02166905 | DEC-205/NY-ESO-1 Fusion Protein | I/II | 2020 | Roswell Park Cancer Institute |
| NCT03017131 | Genetically Engineered NY-ESO-1-specific T Lymphocytes | I | 2020 | Roswell Park Cancer Institute |
| NCT02042430 | Epacadostat + cancer-testis antigen 1B | Early I | 2020 | National Cancer Institute (NCI) |
| NCT01567891 | gene-modified T cells | I/II | 2019 | Adaptimmune |
| NCT00803569 | ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine | I | 2019 | Ludwig Institute for Cancer Research |
| NCT00112957 | Recombinant Vaccinia-NY-ESO-1 and Recombinant Fowlpox-NY-ESO-1 | II | 2018 | Ludwig Institute for Cancer Research |
| NCT00616941 | NY-ESO-1 OLP4 peptide vaccine | I | 2018 | Ludwig Institute for Cancer Research |
| NCT03132922 | Autologous genetically modified MAGE-A4ᶜ¹º³²T cells | I | 2017 | Adaptimmune |
| NCT02015416 | recombinant NY-ESO-1 antigen and the adjuvant GLA-SE | I | 2017 | Immune Design |
| NCT00623831 | Mixed bacteria vaccine | I | 2017 | Ludwig Institute for Cancer Research |
| NCT00373217 | MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine | II | 2016 | Craig L Slingluff, Jr |
| National Cancer Institute (NCI) | ||||
| NCT01522820 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401 | I | 2016 | Roswell Park Cancer Institute |
| NCT01673217 | NY-ESO-1 peptide vaccine | I | 2014 | Roswell Park Cancer Institute |
| NCT00066729 | NY-ESO-1 peptide vaccine | I | 2011 | Memorial Sloan Kettering Cancer Center |